Framework nucleic acid-programmed aptamer–paclitaxel conjugates as targeted therapeutics for triple-negative breast cancer
Nanoscale Horizons · 2025 · 10 (5) · 873-884
DOI: 10.1039/d4nh00652f ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanoscale Horizons, 2025. Verfasst von Lin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo Cixi Institute of Biomedical Engineering, Ningbo Institute of Mate…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Paclitaxel, Aptamers, Nucleotide, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 3315 Innovation Team in Ningbo City, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
A precisely structured framework nucleic acid-programmed aptamer–paclitaxel conjugate with well-defined paclitaxel loading dose is fabricated, enabling the regulation of receptor–aptamer affinity to facilitate tumor-targeted chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering of Chinese Academy of Sciences, Ningb…
- Cancer Care Centre, St George Hospital, Kogarah, NSW, 2217, Australia.
- St. George and Sutherland Clinical Campuses School of Clinical Medicine UNSW Sydney Kensington, NSW 2052, Australia.
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
Förderung
- National Natural Science Foundation of China
- 3315 Innovation Team in Ningbo City
- Natural Science Foundation of Zhejiang Province
- Natural Science Foundation of Ningbo Municipality
Zitieren
APA
Li, L., Wei, P., Kong, T., Yuan, B., Fu, P., Li, Y., Wang, Y., Zheng, J., & Wang, K. (2025). Framework nucleic acid-programmed aptamer–paclitaxel conjugates as targeted therapeutics for triple-negative breast cancer. Nanoscale Horizons, 10(5), 873-884. https://doi.org/10.1039/d4nh00652f
Vancouver
Li L, Wei P, Kong T, Yuan B, Fu P, Li Y, et al. Framework nucleic acid-programmed aptamer–paclitaxel conjugates as targeted therapeutics for triple-negative breast cancer. Nanoscale Horizons. 2025;10(5):873-884. doi:10.1039/d4nh00652f
BibTeX
@article{Li2025,
author = {Li, Lin and Wei, Pengyao and Kong, Tong and Yuan, Bo and Fu, Pan and Li, Yong and Wang, Yuhui and Zheng, Jianping and Wang, Kaizhe},
title = {Framework nucleic acid-programmed aptamer–paclitaxel conjugates as targeted therapeutics for triple-negative breast cancer},
journal = {Nanoscale Horizons},
year = {2025},
volume = {10},
number = {5},
pages = {873--884},
doi = {10.1039/d4nh00652f}
}
EUVIMED